Compare Moderna, Inc. (MRNA) vs Remitly Global Inc (RELY) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

RELY trades at $23.83, down 1.24% on the day, with a bullish technical signal from moving averages. The company has demonstrated a strong turnaround, achieving profitability in 2025 with net income of $67.93 million after years of losses. Revenue growth is robust, reaching $1.64 billion in 2025, with positive cash flow from operations of $325.08 million. Recent news highlights expansion, including a new license in the UAE and raised full-year guidance for 2026.

The outlook is positive, driven by accelerating revenue growth, market share gains in the remittance sector, and a clear path to sustained profitability. Key risks include intense competition from established payment giants and execution challenges in international expansion. With a consensus analyst price target of $28.50 implying significant upside, the stock presents a growth opportunity, though investors should be mindful of its premium valuation multiples.